ArticleScientific reports2025
piRNAs and circRNAs acting as diagnostic biomarkers in clear cell renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- piRNA: Molecular Mechanisms from Germline Silencing to Somatic Regulation and Roles in Disease.International journal of molecular sciences · 2026Review
- Non‑coding RNAs in epithelial‑mesenchymal transition of renal cell carcinoma (Review).Molecular medicine reports · 2026Review
- Emerging roles of PIWI-interacting RNAs in cancer molecular diagnostics and therapeutics: a molecular biosciences perspective.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The discovery of diverse functions and mechanisms in cancer has underscored the significance of emerging non-coding RNAs (ncRNAs), such as PIWI-interacting RNAs (piRNAs) and circular RNAs (circRNAs), within the clinical context of cancer. Understanding their role in clear cell renal cell carcinoma (ccRCC) is imperative and necessitates comprehensive investigation. This study aims to further explore the diagnostic potential of piRNAs and circRNAs for ccRCC. The dysregulated piRNAs and circRNAs in ccRCC were identified using small RNA (sRNA) high-throughput sequencing technology, while their expression in clinical samples was assessed by RT-qPCR. A paired t-test was performed to compare the expression levels of piRNAs and circRNAs between ccRCC and adjacent tissues. Additionally, ROC curve analysis was conducted to evaluate the diagnostic specificity, sensitivity, and area under the curve (AUC) of piRNAs and circRNAs. High-throughput sequencing revealed a significant downregulation of 17 piRNAs and 694 circRNAs in ccRCC tissues, accompanied by a significant upregulation of 5 piRNAs and 490 circRNAs. RT-qPCR analysis demonstrated markedly lower expression levels of piR-has-150997, 133872, 132556, 154502, and uniq-84737 in the ccRCC group compared to the adjacent tissue group (p < 0.05). When considering the combined detection of piR-hsa-150997, piR-hsa-133872, piR-hsa-132556, piR-hsa-154502, uniq_84737, circABCC1, circNETO2_006, and circARID1B_037, the diagnostic AUC for ccRCC was found to be high at an approximate value of AUC = 0.878. The diagnostic performance of piR-has-150997, 133872, 132556, 154502, uniq-84737, circABCC1, circNETO2_006, and circARID1B_037 demonstrates promise for ccRCC. A model incorporating piR-hsa-150997, uniq_84737, circABCC1, circNETO2_006, and circARID1B_037 could serve as an ideal diagnostic marker system with significant clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.